Hepatitis C Virus Clinical Trial
Official title:
Prevalence of Seroconversion of Hepatitis c Virus Among Children With Chronic Kidney Disease on Regular Hemodialysis
observational cross sectional study for children with chronic kidney disease who on regular hemodialysis in assiut univeristy children hospital at dialysis unit, observe prevalence of serological seroconversion of hepatitis c virus and associated risk factors
Hepatitis C virus (HCV) is a blood-borne pathogen that appears to be endemic in many parts of the world,the highest prevalence of HCV has been found in Egypt (17-26%) The prevalence of HCV infection is higher in most subgroups of chronic kidney disease (CKD) patients than in the general population. As there is very little known about HCV infection in infants and children with CKD and this very limited information implies that the current guidelines do not apply directly and completely to this specific population, and as the Kidney Disease Improving Global Outcomes (KDIGO) has recommended that pediatric nephrologists and other physicians - in charge of caring for children with CKD - should carefully evaluate the extent to which the current guidelines may be extrapolated to children. Hepatitis C virus (HCV) infection is a significant cause of morbidity and mortality in hemodialysis patients and observed as a major public health problem infecting 170 million people globally and hepatitis C virus (HCV) infection is one of the most common blood-borne infections in Egypt, a large number of egyptians are exposed to infection due to low hygiene and sterilization measures in our community The Patients who undergo maintenance hemodialysis (HD) treatment are at increased hazard of getting these infections and have a greater prevalence of HCV than the general population due to underlying impaired cellular immunity which increases their susceptibility to HCV infection the hemodialysis patients are exposed to prolonged vascular access and exposure to contaminated equipment and handling by medical staff, In addition the CKD patients require frequent blood transfusion to recover the anemia related with chronic kidney disease and this blood transfusion make a source for HCV infection The inadequate sterilization of medical equipments, invasive dialysis procedures, mode of dialysis, contaminated blood and blood products, duration of end stage kidney disease, sharing of dialysis equipment, insertion of an intravascular catheter and contact with contaminated HD equipments and supplies during hemodialysis, all these risk factors help in HCV infection in hemodialysis patients. In this study, the prevalence of seroconversion of hepatitis c virus among children with CKD on regular hemodialysis is to be assessed and its possible risk factors related to it ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02907996 -
Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in Korea
|
||
Completed |
NCT02207088 -
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
|
Phase 3 | |
Not yet recruiting |
NCT02893046 -
HCV Care Pathway in Ile-de-France
|
N/A | |
Completed |
NCT01428063 -
Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials
|
Phase 2 | |
Completed |
NCT01396005 -
A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123)
|
Phase 1 | |
Completed |
NCT01195181 -
Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.
|
Phase 4 | |
Completed |
NCT00219999 -
Hepatitis C Virus and the Humoral Immune System
|
N/A | |
Completed |
NCT02243293 -
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
|
Phase 2/Phase 3 | |
Completed |
NCT02265237 -
A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)
|
Phase 3 | |
Completed |
NCT02604017 -
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection
|
Phase 3 | |
Withdrawn |
NCT00947245 -
Japanese Bridging Study Conducted in the United States
|
Phase 1 | |
Completed |
NCT01713283 -
Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection
|
Phase 2 | |
Completed |
NCT01458535 -
A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-267 and With and Without Ribavirin (RBV) in Treatment-Naïve Subjects With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)
|
Phase 2 | |
Completed |
NCT01479881 -
A Study in Healthy Participants Investigating the Effect of TMC435 on the Pharmacokinetics of Immunosuppressants Cyclosporine and Tacrolimus
|
Phase 1 | |
Completed |
NCT01241773 -
TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents Efavirenz and Raltegravir
|
Phase 1 | |
Completed |
NCT01193361 -
Ph IIA Study (SOC +/- NS5B)
|
Phase 2 | |
Completed |
NCT01006031 -
Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4
|
Phase 2/Phase 3 | |
Completed |
NCT00819026 -
Observational Trial of Hepatitis C Virus Infected Patients on Calcineurin Inhibitors
|
N/A | |
Completed |
NCT00382798 -
Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and Ribavirin
|
Phase 1/Phase 2 | |
Completed |
NCT02592057 -
Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Chronic Hepatitis C Virus Infection in India
|